PDCD1 and cervical cancer: Also, given that various experiments and expression of some markers on circulating T lymphocytes’ surface and the expression of PD-1 inhibitor molecules on T cells’ surfaces following ipilimumab administration, led to a new perspective for target therapy with PD-1 monoclonal antibody inhibitors in cervical cancer patients (7).